



Q4 2024 Financial Review

February 2025



Disclaimer



This presentation has been prepared by Ceragon Networks Ltd. ("Ceragon" or the "Company") for informational purposes only. This presentation and the information contained herein are proprietary to the Company and may not be reproduced (in whole or in part) nor summarized, used, distributed, disseminated and/or copied without the prior written consent by the Company.

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon in the United States and other countries. CERAGON® is a trademark of Ceragon Networks Ltd., registered in various countries. Other names mentioned are owned by their respective holders.

Neither this presentation nor any of the information contained herein constitute an offer to sell or the solicitation of an offer to buy any securities. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Ceragon's management about Ceragon's business, financial condition, results of operations, micro and macro market trends and other issues addressed or reflected therein. Examples of forward-looking statements include, but are not limited to, statements regarding: projections of demand, revenues, net income, gross margin, capital expenditures and liquidity, competitive pressures, order timing, supply chain and shipping, components availability, growth prospects, product development, financial resources, cost savings and other financial and market matters. You may identify these and other forward-looking statements by the use of words such as "may", "plans", "anticipates", "estimates", "expects", "intends", "potential" or the negative of such terms, or other comparable terminology, although not all forward-looking statements contain these identifying words.

Forward Looking Statements.

Although we believe that the 1projections reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations therefrom will not be material. Such forward-looking statements involve known and unknown risks and uncertainties that may cause Ceragon's future results or performance to differ materially from those anticipated, expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the effects of the evolving nature of the war situation in Israel and the related evolving regional conflicts; the effects of global economic trends, including recession, rising inflation, rising interest rates, commodity price increases and fluctuations, commodity shortages and exposure to economic slowdown; risks associated with the recent acquisition of End 2 End Technologies; risks associated with delays in the transition to 5G technologies and in the 5G rollout; risks relating to the concentration of our business on a limited number of large mobile operators and the fact that the significant weight of their ordering, compared to the overall ordering by other customers, coupled with inconsistent ordering patterns, could negatively affect us; risks resulting from the volatility in our revenues, margins and working capital needs; disagreements with tax authorities regarding tax positions that we have taken could result in increased tax liabilities; the high volatility in the supply needs of our customers, which from time to time lead to delivery issues and may lead to us being unable to timely fulfil our customer commitments; and such other risks, uncertainties and other factors that could affect our results of operation, as further detailed in Ceragon's most recent Annual Report on Form 20-F, as published on March 21, 2024, as well as other documents that may be subsequently filed by Ceragon from time to time with the Securities and Exchange Commission.

We caution you not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Ceragon does not assume any obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release unless required by law.

While we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. In addition, any forward-looking statements represent Ceragon's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Ceragon does not assume any obligation to update any forward-looking statements unless required by law.

The results reported in this press-release are preliminary and unaudited results, and investors should be aware of possible discrepancies between these results and the audited results to be reported, due to various factors.


Ceragon's public filings are available on the Securities and Exchange Commission's website at www.sec.gov and may also be obtained from Ceragon's website at www.ceragon.com. Industry Data.


This presentation contains estimates and information that is based on industry publications, reports and peer company public filings. This information involves a number of assumptions and limitations, and you are cautioned not to rely on or give undue weight to this information. The Company has not independently verified the accuracy or completeness of the data contained in these industry publications, reports or filings.

Revenues - Geographic Split



| | Q4/21 | Q1/22 | Q2/22 | Q3/22 | Q4/22 | Q1/23 | Q2/23 | Q3/23 | Q4/23 | Q1/24 | Q2/24 | Q3/24 | Q4/24 |
|---------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| India | 30% | 22% | 31% | 28% | 29% | 24% | 31% | 34% | 34% | 29% | 37% | 49% | 52% |
| EMEA | 23% | 25% | 21% | 18% | 20% | 20% | 17% | 15% | 19% | 17% | 20% | 14% | 15% |
| North America | 16% | 19% | 21% | 27% | 23% | 32% | 26% | 26% | 27% | 33% | 24% | 24% | 12% |
| APAC | 10% | 14% | 11% | 10% | 11% | 12% | 11% | 10% | 7% | 9% | 9% | 6% | 11% |
| Latin America | 21% | 20% | 16% | 17% | 17% | 12% | 15% | 15% | 13% | 12% | 10% | 7% | 10% |
| Total | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |





NON-GAAP Profit & Loss



| | · · | | | | | | | | | | | | |
|------------------------------------|---------|---------|--------------|------------|-------------|--------------|-----------|--------|--------|--------|--------|---------|---------|
| | | (U.S | . dollars in | thousands, | except shar | e and per sh | are data) | | | | | | |
| | Q4/21 | Q1/22 | Q2/22 | Q3/22 | Q4/22 | Q1/23 | Q2/23 | Q3/23 | Q4/23 | Q1/24 | Q2/24 | Q3/24 | Q4/24 |
| Revenues | 77,760 | 70,319 | 70,674 | 78,649 | 75,531 | 83,409 | 86,151 | 87,260 | 90,359 | 88,498 | 96,088 | 102,672 | 106,932 |
| Cost of Revenues | 55,199 | 50,850 | 49,142 | 50,699 | 50,551 | 55,053 | 55,747 | 56,844 | 58,599 | 55,986 | 62,304 | 67,434 | 70,240 |
| Gross profit | 22,561 | 19,469 | 21,532 | 27,950 | 24,980 | 28,356 | 30,404 | 30,416 | 31,760 | 32,512 | 33,784 | 35,238 | 36,692 |
| Gross margin | 29.0% | 27.7% | 30.5% | 35.5% | 33.1% | 34.0% | 35.3% | 34.9% | 35.1% | 36.7% | 35.2% | 34.3% | 34.3% |
| Research & Development | 7,745 | 6,779 | 7,493 | 7,150 | 7,863 | 7,692 | 7,580 | 7,260 | 7,715 | 8,695 | 8,201 | 8,577 | 8,777 |
| % R&D | 10.0% | 9.6% | 10.6% | 9.1% | 10.4% | 9.2% | 8.8% | 8.3% | 8.5% | 9.8% | 8.5% | 8.4% | 8.2% |
| Sales & Marketing | 8,681 | 8,495 | 9,060 | 8,280 | 8,605 | 9,820 | 9,415 | 9,702 | 10,175 | 10,694 | 11,004 | 10,413 | 10,628 |
| % S&M | 11.2% | 12.1% | 12.8% | 10.5% | 11.4% | 11.8% | 10.9% | 11.1% | 11.3% | 12.1% | 11.5% | 10.1% | 9.9% |
| General & Administration | 4,616 | 4,803 | 4,612 | 6,116 | 17,647 | 4,956 | 6,051 | 5,451 | 6,098 | 5,538 | 1,434 | 404 | 5,098 |
| % G&A | 5.9% | 6.8% | 6.5% | 7.8% | 23.4% | 5.9% | 7.0% | 6.2% | 6.7% | 6.3% | 1.5% | 0.4% | 4.8% |
| Total operating expenses | 21,042 | 20,077 | 21,165 | 21,546 | 34,115 | 22,468 | 23,046 | 22,413 | 23,988 | 24,926 | 20,639 | 19,393 | 24,504 |
| Operating profit (loss) | 1,519 | (608) | 367 | 6,404 | (9,135) | 5,888 | 7,358 | 8,003 | 7,772 | 7,585 | 13,145 | 15,844 | 12,189 |
| Operating margin | 2.0% | -0.9% | 0.5% | 8.1% | -12.1% | 7.1% | 8.5% | 9.2% | 8.6% | 8.6% | 13.7% | 15.4% | 11.4% |
| Financial expenses and others, net | 2,691 | 1,184 | 2,531 | 2,011 | 2,858 | 1,816 | 2,171 | 2,086 | 2,538 | 2,300 | 2,600 | 1,211 | 3,493 |
| Income Tax | 855 | 61 | 304 | 269 | 534 | 439 | 787 | 953 | 1,492 | 542 | 609 | 580 | 1,047 |
| Non GAAP Net income (loss) | (2,027) | (1,853) | (2,468) | 4,124 | (12,527) | 3,633 | 4,400 | 4,964 | 3,742 | 4,743 | 9,936 | 14,053 | 7,650 |
| Non GAAP EPS | (0.02) | (0.02) | (0.03) | 0.05 | (0.15) | 0.04 | 0.05 | 0.06 | 0.04 | 0.05 | 0.11 | 0.16 | 0.09 |
| # of Shares for diluted EPS ('000) | 83,916 | 83,959 | 84,019 | 85,970 | 84,348 | 86,712 | 86,747 | 87,228 | 85,054 | 87,585 | 87,922 | 88,334 | 89,988 |



Selected Cash Flow Data

| (U.S. dollars in thousands) | | | | | | | | | | | | | |
|---|----------|---------|---------|---------|---------|---------|---------|---------|----------|---------|---------|---------|---------|
| | Q4/21 | Q1/22 | Q2/22 | Q3/22 | Q4/22 | Q1/23 | Q2/23 | Q3/23 | Q4/23 | Q1/24 | Q2/24 | Q3/24 | Q4/24 |
| Total cash & cash equivalents | 17,079 | 24,960 | 23,592 | 25,964 | 22,948 | 26,423 | 24,529 | 33,966 | 28,237 | 28,783 | 26,303 | 34,014 | 35,311 |
| Cash flow from operations | (9,740) | (1,816) | (3,173) | 8,597 | (8,503) | 3,509 | 3,181 | 13,237 | 10,961 | 6,527 | 4,822 | 13,720 | 1,129 |
| Capital expenditures | (3,328) | (2,726) | (3,079) | (4,487) | (2,129) | (4,430) | (2,879) | (2,381) | (11,180) | (3,706) | (5,238) | (3,148) | (4,372) |
| Options Exercise | 42 | 81 | 32 | 297 | - | - | 30 | - | 9 | 258 | 284 | 265 | 5,071 |
| Proceeds (repayment) of short-term bank credits and loans, net | 2,900 | 12,150 | 4,950 | (2,000) | 7,600 | 4,350 | (2,300) | (1,350) | (5,600) | (2,100) | (2,050) | (3,250) | - |
| Effect of exchange rate changes on cash and cash equivalents, and other | (30) | 192 | (98) | (35) | 16 | 46 | 74 | (64) | 81 | (433) | (298) | 124 | (531) |
| Net Change in Cash | (10,156) | 7,881 | (1,368) | 2,372 | (3,016) | 3,475 | (1,894) | 9,437 | (5,729) | 546 | (2,480) | 7,711 | 1,297 |

Selected Balance Sheet Data



| (U.S. dollars in thousands, except DSO data) | | | | | | | | | | | | | |
|--|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| | Q4/21 | Q1/22 | Q2/22 | Q3/22 | Q4/22 | Q1/23 | Q2/23 | Q3/23 | Q4/23 | Q1/24 | Q2/24 | Q3/24 | Q4/24 |
| Cash and Cash Equivalents | 17,079 | 24,960 | 23,592 | 25,964 | 22,948 | 26,423 | 24,529 | 33,966 | 28,237 | 28,783 | 26,303 | 34,014 | 35,311 |
| Trade Receivables | 118,310 | 120,682 | 122,734 | 115,871 | 100,034 | 100,590 | 107,592 | 104,593 | 104,321 | 97,386 | 112,895 | 121,550 | 149,619 |
| DSOs | 149 | 150 | 152 | 142 | 124 | 119 | 121 | 115 | 110 | 101 | 114 | 118 | 139 |
| Inventory | 61,398 | 58,060 | 60,710 | 64,227 | 72,009 | 68,742 | 67,836 | 70,050 | 68,811 | 61,029 | 59,490 | 59,800 | 59,693 |
| Inventory Days | 111 | 103 | 107 | 114 | 130 | 122 | 116 | 117 | 110 | 97 | 92 | 88 | 85 |
| Working capital | 87,799 | 87,494 | 82,105 | 83,335 | 77,911 | 79,518 | 83,536 | 88,405 | 84,987 | 84,235 | 88,966 | 101,862 | 109,590 |
| Short-term loans | 14,800 | 26,950 | 31,900 | 29,900 | 37,500 | 41,850 | 39,550 | 38,200 | 32,600 | 30,500 | 28,450 | 25,200 | 25,200 |
| Shareholders' Equity | 137,151 | 135,856 | 131,973 | 132,757 | 119,783 | 122,808 | 126,382 | 130,514 | 134,019 | 135,017 | 143,501 | 157,172 | 166,324 |
| % - Shareholders' Equity/ Total assets | 47% | 45% | 43% | 44% | 41% | 42% | 43% | 43% | 45% | 47% | 48% | 50% | 48% |
| Total Balance Sheet | 292,563 | 300,187 | 304,980 | 302,336 | 289,318 | 290,316 | 294,464 | 301,134 | 298,525 | 286,379 | 299,035 | 317,274 | 344,996 |

Reported results – Reconciliation to GAAP



| | (U.S. dollars in thousands, except share and per share data) | | | | | | | | | | | | |
|---|--|---------|---------|--------|----------|--------|--------|--------|---------|--------|--------|--------|--------|
| | Q4/21 | Q1/22 | Q2/22 | Q3/22 | Q4/22 | Q1/23 | Q2/23 | Q3/23 | Q4/23 | Q1/24 | Q2/24 | Q3/24 | Q4/24 |
| Non GAAP Net income (loss) | (2,027) | (1,853) | (2,468) | 4,124 | (12,527) | 3,633 | 4,400 | 4,964 | 3,742 | 4,743 | 9,936 | 14,053 | 7,650 |
| Stock based compensation expenses | 891 | 746 | 689 | 1,167 | 958 | 1,170 | 810 | 1,048 | 938 | 904 | 1,566 | 907 | 921 |
| Changes in indirect tax positions | (399) | - | 1 | 1 | 279 | (0) | - | - | - | - | - | - | - |
| Amortization of acquired intangible assets | - | - | - | - | - | - | - | - | 106 | 460 | 306 | 306 | 306 |
| Excess cost on acquired inventory in business combination | - | - | - | - | - | - | - | - | 525 | 124 | - | - | - |
| Loss from termination of joint development agreement | - | - | - | - | - | - | - | - | 1,199 | - | - | - | - |
| Restructuring and related charges | - | - | - | - | - | - | 897 | - | - | 1,416 | - | - | - |
| Acquisition -and integration-related costs | - | - | - | - | - | - | - | 283 | 835 | 462 | 915 | - | 283 |
| Retired CEO compensation | - | (96) | - | - | - | - | - | - | - | - | - | - | - |
| Hostile attempt related costs | - | - | - | 3,971 | 249 | - | - | - | - | - | - | - | - |
| Settlement of Class Action Claimed in 2015 | - | - | - | - | - | - | - | - | - | - | - | - | 1,160 |
| Leases - financial expenses (income) | 706 | (425) | (1,774) | (233) | 154 | (358) | (285) | (364) | 754 | (112) | (207) | 501 | (15) |
| Non-cash revaluation associated with acquisition | - | - | - | - | - | - | - | - | 110 | 673 | (477) | 122 | 1,385 |
| Non-cash tax adjustments | 8,987 | 210 | 136 | 81 | 851 | 853 | 890 | 630 | 478 | 413 | - | - | - |
| GAAP Net Income (Loss) | (12,212) | (2,288) | (1,520) | (863) | (15,018) | 1,968 | 2,088 | 3,367 | (1,203) | 403 | 7,833 | 12,217 | 3,610 |
| GAAP EPS | (0.15) | (0.03) | (0.02) | (0.01) | (0.18) | 0.02 | 0.02 | 0.04 | (0.01) | 0.00 | 0.09 | 0.14 | 0.04 |
| # of Shares for basic EPS ('000) | 83,916 | 83,959 | 84,019 | 84,200 | 84,348 | 84,354 | 84,365 | 84,689 | 85,054 | 85,521 | 85,744 | 86,280 | 87,208 |
| # of Shares for diluted EPS ('000) | 83,916 | 83,959 | 84,019 | 84,200 | 84,348 | 84,992 | 85,313 | 85,488 | 85,054 | 87,585 | 87,922 | 88,334 | 89,988 |

Quarterly Revenues and Non-GAAP Net Income (Loss) CERAGON

